EU Officials Recall Some Valsartan Medicines Due to Impurity EU Officials Recall Some Valsartan Medicines Due to Impurity
The European Medicines Agency is reviewing the medicines after an impurity, thought to be a probable human carcinogen, was detected in the active ingredient supplied by a Chinese company.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
Common heart drug recalled amid fears it could cause cancer
The Medicines and Healthcare products Regulatory Agency revealed the fault stems from a Chinese facility making the active substance valsartan. (Source: the Mail online | Health)
Source: the Mail online | Health - July 5, 2018 Category: Consumer Health News Source Type: news
Common heart drug recalled amid fears it could cause cancer
The Medicines and Healthcare products Regulatory Agency revealed the fault stems from a Chinese facility making the active substance valsartan. (Source: the Mail online | Health)
Source: the Mail online | Health - July 5, 2018 Category: Consumer Health News Source Type: news
Class 1 Medicines Recall: Action Now including out of hours Pharmacy Level Recall: Valsartan capsules and tablets
The Medicines& Healthcare products Regulatory Agency (MHRA) hasissued a Class 1 Medicines Recall. Pharmacies in the UK are being advised to recall all batches of valsartan containing medicines ma (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - July 5, 2018 Category: Drugs & Pharmacology Source Type: news
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto ®
Novartis announced today new real world evidence from the CHAMP-HF registry comparing Entresto® (sacubitril/valsartan) patients to patients not taking Entresto.[1] This pre-specified analysis of an interim data cut from the CHAMP-HF registry showed that chronic heart failure (HF) patients with reduced ejection fraction (HFrEF) taking Entresto reported early, statistically significant improvement in health status, as measured by the KCCQ-12 overall summary score (KCCQ-OS). (Source: World Pharma News)
Source: World Pharma News - May 28, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Research Scandal Involving Popular Heart Drug Engulfs Three More Papers
The scientists involved have hired lawyers to fight the conclusions of a recent investigation into some studies of Diovan in Japan. (Source: The Scientist)
Source: The Scientist - May 4, 2018 Category: Science Tags: Daily News,News & Opinion,The Scientist Source Type: news
Sex, Intimacy Improved on Sacubitril/Valsartan in Heart Failure Sex, Intimacy Improved on Sacubitril/Valsartan in Heart Failure
Quality-of-life gains were strongest in the domains that patients care about most, those reflecting activity and social engagement, say researchers about participants in the PARADIGM-HF trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 10, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
Sacubitril/valsartan good value for money in HF-REF
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2018 Category: Drugs & Pharmacology Source Type: news
Prexxartan (Valsartan Oral Solution) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 28, 2017 Category: Drugs & Pharmacology Source Type: news
Medicure Announces FDA Approval Received for Prexxartan (valsartan) Oral Solution
WINNIPEG, Dec. 19, 2017 /PRNewswire/ - Medicure Inc. ( " Medicure " or the " Company " ) (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that Carmel Biosciences, Inc. ( " Carmel " ) has received final approval of its New Drug Application from... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 19, 2017 Category: Drugs & Pharmacology Source Type: news
New Novartis Entresto ® real world evidence data shows beneficial impact on quality of life in people living with heart failure
Novartis has announced new results from a real-world database study of patients in Germany prescribed Entresto® (sacubitril/valsartan) for heart failure with reduced ejection fraction (HFrEF). The findings further substantiate the beneficial effect of Entresto on heart failure symptoms and patients' quality of life observed in the PARADIGM-HF study and in other real-world cohorts. (Source: World Pharma News)
Source: World Pharma News - November 13, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Commercialization of Generics Impacts Adverse Event Rates
Adverse events up for generic users of losartan, valsartan, candesartan in month of commercialization (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 4, 2017 Category: Respiratory Medicine Tags: Cardiology, Family Medicine, Geriatrics, Gynecology, Internal Medicine, Emergency Medicine, Nephrology, Neurology, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news
